|
US5175320A
(en)
|
1989-04-17 |
1992-12-29 |
Giuliani S.P.A. |
Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
|
|
ES2306459T3
(es)
|
1996-05-23 |
2008-11-01 |
Novartis Ag |
Prevencion y tratamiento de adenoma colonico o microadenoma colonico mediante acido 6-fluoroursodesoxicolico (6-fudca).
|
|
ES2248581T3
(es)
|
2001-03-12 |
2006-03-16 |
Intercept Pharmaceuticals, Inc. |
Esteroides como agonistas de fxr.
|
|
CA2466033A1
(en)
|
2001-11-08 |
2003-05-15 |
The University Of Chicago |
Method of treating disorder related to high cholesterol concentration
|
|
EP1568706A1
(en)
|
2004-02-26 |
2005-08-31 |
Intercept Pharmaceuticals, Inc. |
Novel steroid agonist for FXR
|
|
PL1734970T3
(pl)
|
2004-03-12 |
2015-05-29 |
Intercept Pharmaceuticals Inc |
Leczenie zwłóknienia z zastosowaniem ligandów FXR
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
CN101395170A
(zh)
|
2006-02-14 |
2009-03-25 |
英特塞普特药品公司 |
用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
|
|
US7932244B2
(en)
|
2006-06-27 |
2011-04-26 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
|
|
KR101555716B1
(ko)
|
2007-01-19 |
2015-09-25 |
인터셉트 파마슈티컬즈, 인크. |
Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
|
|
WO2010014836A2
(en)
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
ES2774368T3
(es)
|
2008-11-19 |
2020-07-20 |
Intercept Pharmaceuticals Inc |
Moduladores de TGR5 y métodos de uso de los mismos
|
|
DK2698375T3
(en)
|
2008-11-19 |
2018-05-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulators and methods for using them
|
|
SI3336097T1
(sl)
|
2012-06-19 |
2021-07-30 |
Intercept Pharmaceuticals, Inc. |
Priprava nekristalinične oblike obetiholne kisline
|
|
SG11201503247UA
(en)
|
2012-10-26 |
2015-06-29 |
Intercept Pharmaceuticals Inc |
Process for preparing bile acid derivatives
|
|
US20140206657A1
(en)
|
2013-01-18 |
2014-07-24 |
City Of Hope |
Bile acid analog tgr5 agonists
|
|
CN105164161A
(zh)
|
2013-03-13 |
2015-12-16 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
|
TN2015000497A1
(en)
|
2013-05-14 |
2017-04-06 |
Intercept Pharmaceuticals Inc |
11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
|
|
CN104938001B
(zh)
|
2013-12-10 |
2019-04-12 |
华为终端有限公司 |
一种注册方法和相关节点以及注册系统
|
|
SG11201703717SA
(en)
|
2014-11-06 |
2017-06-29 |
Enanta Pharm Inc |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
|
KR102546748B1
(ko)
|
2014-11-19 |
2023-06-22 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-3,7-다이온 스테로이드
|
|
KR102527821B1
(ko)
|
2014-11-19 |
2023-05-02 |
엔제트피 유케이 리미티드 |
스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
|
|
EA033445B1
(ru)
|
2014-11-19 |
2019-10-31 |
Nzp Uk Ltd |
5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
|
|
WO2016086134A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
EP3223823A4
(en)
|
2014-11-26 |
2018-10-17 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
US11578097B2
(en)
|
2014-11-26 |
2023-02-14 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
|
|
CN105348365A
(zh)
|
2014-12-03 |
2016-02-24 |
四川百利药业有限责任公司 |
一种胆酸衍生物及其制备方法、药物组合物和用途
|
|
TW201628625A
(zh)
|
2015-02-06 |
2016-08-16 |
英特賽普醫藥品公司 |
組合療法醫藥組成物
|
|
EP3256134A4
(en)
|
2015-02-11 |
2018-10-03 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
CN107530361A
(zh)
|
2015-03-09 |
2018-01-02 |
英特塞普特医药品公司 |
用于调节骨密度的方法
|
|
WO2016145216A1
(en)
|
2015-03-10 |
2016-09-15 |
Metselex, Inc. |
Fluorinated and alkylated bile acids
|
|
US20160279393A1
(en)
|
2015-03-25 |
2016-09-29 |
Covidien Lp |
Guidewire retrieval catheter
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
US10894054B2
(en)
|
2015-04-07 |
2021-01-19 |
Intercept Pharmaceuticals, Inc. |
FXR agonist compositions for combination therapy
|
|
PE20180690A1
(es)
|
2015-04-27 |
2018-04-23 |
Intercept Pharmaceuticals Inc |
Composiciones de acido obeticolico y metodos de uso
|
|
WO2016173493A1
(en)
*
|
2015-04-28 |
2016-11-03 |
Shanghai De Novo Pharmatech Co. Ltd. |
Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof
|
|
JP2018519246A
(ja)
*
|
2015-04-28 |
2018-07-19 |
ジエンス ハンセン ファーマセウティカル グループ カンパニー リミテッド |
コール酸誘導体、及びその製造方法及び医薬用途
|
|
TW201704251A
(zh)
|
2015-04-29 |
2017-02-01 |
正大天晴藥業集團股份有限公司 |
鵝去氧膽酸衍生物
|
|
CN106210599B
(zh)
|
2015-04-30 |
2021-02-12 |
中兴通讯股份有限公司 |
一种多画面调整方法、装置及多点控制单元
|
|
JP6861703B2
(ja)
|
2015-06-19 |
2021-04-21 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
Ｔｇｒ５修飾物質およびその使用方法
|
|
KR20180030204A
(ko)
|
2015-07-30 |
2018-03-21 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 및 이의 유도체를 제조하는 방법
|
|
US10604544B2
(en)
|
2015-08-07 |
2020-03-31 |
Intercept Pharmaceuticals, Inc. |
Methods for preparation of bile acids and derivatives thereof
|
|
CN106518946A
(zh)
*
|
2015-09-10 |
2017-03-22 |
上海迪诺医药科技有限公司 |
磺酰脲衍生物、其药物组合物及应用
|
|
CA2998876A1
(en)
|
2015-09-21 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods of promoting hepatic regeneration
|
|
AU2016325619A1
(en)
|
2015-09-24 |
2018-04-12 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation bile acid derivatives
|
|
MA42339A1
(fr)
|
2015-10-07 |
2019-01-31 |
Intercept Pharmaceuticals Inc |
Modulateurs du récepteur farnésoïde x
|
|
AU2016350690C1
(en)
|
2015-11-06 |
2020-04-23 |
Intercept Pharmaceuticals, Inc. |
Methods for the preparation of obeticholic acid and derivatives thereof
|
|
JP2018538331A
(ja)
|
2015-12-22 |
2018-12-27 |
インターセプト ファーマシューティカルズ， インコーポレイテッド |
オベチコール酸の多型結晶形態
|
|
CN105646634A
(zh)
|
2016-01-29 |
2016-06-08 |
中国药科大学 |
奥贝胆酸杂质的制备方法
|
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
|
US10323060B2
(en)
|
2016-02-23 |
2019-06-18 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
|
|
WO2017147159A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
ES2874682T3
(es)
|
2016-03-11 |
2021-11-05 |
Intercept Pharmaceuticals Inc |
Derivados de 3-desoxi y composiciones farmacéuticas de los mismos
|
|
GB201608777D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Compounds
|
|
GB201608779D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|
|
GB201608776D0
(en)
|
2016-05-18 |
2016-06-29 |
Dextra Lab Ltd |
Methods and compounds
|